The rapid spread of Zika virus (ZIKV) and its association with abnormal brain development constitute a global health emergency. Congenital ZIKV infection produces a range of mild to severe pathologies, including placental damage and microcephaly. However, the placenta's role in viral transmission and the mechanisms of microcephaly have not been addressed in primary human tissues. Moreover, there is an urgent need for drugs that can prevent developmental defects following infection. Here, we identify the placental and brain cell populations most susceptible to ZIKV infection, provide evidence for a mechanism of viral entry, and show that a commonly used antibiotic protects cultured brain cells by inhibiting viral proliferation. In the early gestation placenta, the virus readily infected trophoblast subpopulations that are in direct contact with maternal blood and uterine cells, suggesting routes of ZIKV transmission to the embryo and fetus. In the brain, ZIKV preferentially infected neural stem cells, astrocytes, and microglia, Understanding the cell types initially vulnerable to ZIKV infection may help to reveal routes of viral spread, mechanisms underlying fetal abnormalities, and relevant cellular targets for testing therapeutic compounds. The enriched expression of candidate flavivirus entry proteins in specific cell populations suggests that reduced cellular models may not capture the diversity of cell types that could be vulnerable to infection. To study ZIKV infection in the context of the complexities of placental and brain architecture in vivo, we exposed organotypic tissue cultures of the placenta and cerebral cortex from relevant developmental stages to three strains of ZIKV: Cambodia 2010 FSS13025 (ZIKV-CAM), Brazil 2015 SPH2015 (ZIKV-BR), and Puerto Rico 2015 PRVABC59 (ZIKV-PR), see Methods.
In clinical reports, viral infection of the placenta and resulting pathology indicate that some fetal abnormalities, including growth restriction, may be attributable to infection of the placenta itself rather than to transplacental passage of the virus and infection of the embryo and fetus 1 . However, recent analyses suggest that trophoblasts isolated from placentas at term are poorly permissive to ZIKV infection 2,3 . To explore viral transmission during early pregnancy when the formative stages of brain development take place, we utilized an organotypic culture system of chorionic villus explants from first and second trimester human placentas. These organoids contain the trophoblast (TB) cell types that are in direct contact with maternal blood and/or cells of the uterus: multi-nucleated syncytiotrophoblasts (STBs) that form the villus surface and cell columns, which contain mononuclear cytotrophoblasts (CTBs) that are destined to invade the uterus and its resident blood vessels (diagrammed in Extended Data Fig.   1 ). The explants were cultured for 24 h prior to infection, which enabled re-establishment of their basic architecture, including cell column outgrowths.
Immunostaining with an antibody against the flavivirus envelope protein enabled visualization of infection.
STBs and CTBs were distinguished by cytokeratin (CK) expression. Twenty-four hours post-infection (hpi) with ZIKV-BR we observed patches of STBs at the villus surface that were immuno-positive for the viral protein. Occasionally the underlying CTBs also reacted with the antibody (Fig. 1a ). The explant model includes CTB outgrowths, the in vitro equivalent of cell column extensions, that were also infected ( Fig. 1b) . In some areas, there was evidence of infected CK-negative stromal elements ( Fig. 1b, upper left). During the first trimester, the same pattern of ZIKV infection was observed with all the strains that were tested (Extended Data Fig. 2 ). Freshly isolated CTBs purified from first or second trimester placentas were also susceptible to infection (Extended Data Fig. 3 ). Second trimester explants had many fewer foci of infection than the first trimester cultures, but the pattern of STB and CTB staining with anti-flavivirus envelope protein was the same (Fig. 1c) . At this stage, cell columns, which are largely depleted of CTBs, no longer form in culture and thus could not be analyzed. The patterns of gestationalage related changes in susceptibility to infection mirrored the decline in expression of the putative ZIKV receptor, AXL, in CTBs and STBs from first to second trimester (Extended Data Fig. 4 
and 5).
Interestingly, infection of STBs and CTBs was associated with disorganized cytokeratin, revealing possible evidence of cellular damage (Fig. 1a ). Furthermore, immunoblotting showed that infection was accompanied by increased expression of AXL and markers of autophagy, LC3B and p62 (Extended Data Fig. 3 ). Together, these data showed that the TB cell types that are in direct contact with maternal blood and the uterine wall are susceptible to ZIKV infection during the first half of pregnancy, indicating vulnerability at stages relevant to fetal abnormalities and suggesting routes of placental infection across floating villi or via the cell columns of anchoring villi that are attached to the uterine wall.
After crossing the placenta, ZIKV is neurotropic, as established by the detection of viral RNA and flavivirus particles in post-mortem brain tissue of infants with microcephaly 4 . Recent studies have begun to study the consequences of infection in permissive mouse strains and in neural cells dissociated from primary tissue 5 or derived in vitro from human induced pluripotent stem (iPS) cells [6] [7] [8] [9] . In the developing mouse brain, ZIKV was found in radial glia, the neural stem cells of the developing brain, and in neurons 10 . ZIKV infection of human iPS-derived neural cells and cerebral organoids highlighted the selective vulnerability of progenitor cells resulting in their apoptotic cell death 6, 9 . A study of isolated primary human neural progenitor cells showed ZIKV was initially cytopathic, but that viral replication persisted for weeks in surviving cells 5 . However, none of these models fully recapitulates the developmental events and cell types present during human brain development, and it is unclear how well the models represent ZIKVinduced pathology in human fetuses. Previous studies suggested that enriched expression of AXL by specific cell types could confer vulnerability of those cells to ZIKV entry 11 . Based on the expression of the candidate entry factor AXL, we predicted that radial glia, astrocytes, microglia, and cells lining blood vessels may be particularly vulnerable to infection 12 . Therefore, we next investigated the infectivity of ZIKV in developing human brain using organotypic cultures from primary tissue that preserve tissue architecture, cell behaviors, and many aspects of cell diversity.
In tissue samples from peak stages of neurogenesis (13-16 post-conception week (pcw)), we observed high levels of infection in the ventricular and subventricular zones where radial glia and newborn neurons reside ( Fig. 2a ). We found that the virus preferentially infected radial glia cells across the germinal zone ( Fig. 2b) . A minor fraction of cells positive for ZIKV at these stages included postmitotic neurons, that may represent neurons generated from infected radial glia. Interestingly, we observed clusters of infected radial glia in the germinal zone ( Fig. 2b) , which may reflect spread of the virus from initially infected cells to neighboring radial glia. We observed similar patterns of infection across strains (Extended Data Fig.   6 ), but we did not observe appreciable cell death (Extended Data Fig. 7) . The finding of preferential radial glia infection and survival in organotypic slices is consistent with experiments in cultured primary human neural stem cells 5 and developing mouse cortex 10 . Recent studies of dissociated and in vitro derived neural stem cells also reported cell death in neural stem cells 6, 9, 13 not observed here. These observations could reflect differences in maturation stage and culture conditions of cells or in the viral titer and duration of exposure. Even without immediately causing cell death, ZIKV infection of radial glia cells could affect cell cycle progression 10, 13 , neuronal differentiation, or the migration and survival of newborn daughter neurons. These mechanisms would be comparable to many genetic causes of microcephaly and lissencephaly that affect radial glia progenitor cells and neuronal migration 14 .
At later stages of development (after 18 pcw), we observed broad infection of radial glia in the germinal zones. In addition, we observed high infectivity in the cortical plate and subplate where the two principal descendants of radial glia, neurons and astrocytes, migrate during the generation of the cerebral cortex ( Fig. 3) . Among cortical plate cells, we observed a high rate of infection of astrocytes ( Fig. 3a,d,e ), consistent with the high level of AXL expression in this cell type 12 . We also observed infection of oligodendrocyte precursor cells (OPCs) and microglia, but there was limited infection of neurons or evidence of exacerbated cell death across developmental stages at 72 hpi (Fig. 3b,c) . No major differences in cell type-specific infectivity were observed across the three strains of ZIKV in our short term cultures (Extended Data Fig. 7) . The high levels of infection in astrocytes, many of which contact microcapillaries, could link our understanding of initial infection with clinical findings of cortical plate damage. For example, after prolonged infection, viral production in astrocytes could lead to a higher viral load in the cortical plate causing infection of additional cortical cell types, and astrocyte loss could lead to inflammation and further damage. Widespread cell death of cortical plate populations is expected based on clinical reports of band-like calcifications in the cortical plate, cortical thinning, and hydrocephalus 4, 15 .
Based on the high infectivity of astrocytes in the cortical plate and the clinical findings of cortical plate abnormalities, we further analyzed mechanisms of viral entry in human astrocytes. Recent experiments demonstrated that blocking AXL in skin and lung epithelial cell culture substantially reduced ZIKV entry 11 and blocking AXL in astrocytes similarly reduced dengue virus entry 16 . To test the hypothesis that AXL receptor is involved in mediating ZIKV entry into human astrocytes, we cultured astrocytes derived in vitro from human pluripotent stem cells (hPSCs) 17, 18 and infected them with ZIKV. At 2 hpi, we observed increased protein levels of AXL and the autophagy marker LC3B in astrocyte lysates as with lysates of placental CTBs at 72 hpi (Extended Data Fig. 7) . We next pre-incubated the astrocytes with an antibody that blocks the extracellular domain of AXL before infecting with ZIKV. We found that blocking AXL substantially reduced the infection of astrocytes at an MOI of 10 ( Fig. 3f) . The blocking antibody results are consistent with a model in which AXL contributes to virus entry into cells.
We next searched for pharmacological methods to prevent or diminish the effects of ZIKV infection in human cells through a cytopathic effect (CPE)-based assay. We used U87 cells, a glioblastoma line that expresses high levels of astrocyte and radial glia marker genes 19 . U87 cells infected with ZIKV show a profound CPE at 48 hpi, with significant cell death occurring at 72 hpi (data not shown). Recent reports suggested that chloroquine, a drug historically used to treat or prevent malaria, could protect cells against ZIKV-induced death 20 . We observed a modest protective effect against ZIKV-induced CPE using chloroquine at 2-10 μM, but observed dramatic toxicity of the drug at over 10 μM (data not shown).
We further examined compounds from the macrolide class for protective effects. This class of drugs includes widely used antibiotics that are safe during pregnancy 21 , and certain macrolide antibiotics have been documented to block flavivirus replication 22 . By monitoring viral envelope production, we found that a commonly used macrolide, azithromycin (AZ), dramatically reduced ZIKV-induced CPE in U87 cells ( Fig. 4a) , and inhibited viral proliferation thereby limiting infection in U87 cells and in hPSC-derived astrocytes ( Fig. 4b and c, Extended Data Fig. 8) . These effects were observed at an EC50 of 6 μM for cell viability, or 3-8 μM for inhibition of viral proliferation. These concentrations are comparable to those measured in placental tissues following maternal dosing of AZ 23, 24 and in adult brain tissue 25 . Although the mechanism of action remains unknown, the inhibition of ZIKV by AZ may serve as a launching point toward finding additional potent and safe therapeutics in the context of pregnancy.
Together, our work highlights cell type specific patterns of ZIKV infection in the first and second trimester human placenta and developing brain, provides experimental evidence that AXL mediates ZIKV entry into relevant human brain cells, and suggests a candidate therapeutic agent that could be rapidly implemented to combat ZIKV pathophysiology in pregnant women. While preventative measures, such as mosquito abatement and a ZIKV vaccine, are imperative for long term control of this pathogen, small molecule therapeutics are also of great interest for prophylactic use or the treatment of acute infections in the context of pregnancy. We find that a common antibiotic, the macrolide azithromycin, has surprising activity against ZIKV through an unknown mechanism. Although the macrolides are known as antibacterial agents, previous work has shown that a related class of compounds, the avermectins, possess potent inhibitory activity against a range of flaviviruses, including yellow fever virus, dengue virus, and Japanese encephalitis virus 22 . Importantly, the macrolides are generally known to be safe in the context of pregnancy, which raises the possibility that oral macrolides could be used to mitigate or prevent the harmful effects of ZIKV infection in the unborn. Future work will be required to determine whether macrolides are capable of reducing ZIKV infection or replication in the critical tissues and cell types of the placenta and developing brain.
Online Methods

Cell lines
Vero and U87 cell lines were cultured in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum, 2 mM L-glutamine, 100 U/ml penicillin-streptomycin, and 10 mM HEPES buffer at 37 °C with 5 % CO2. Human astrocytes (after 8 months of in vitro development) were derived from pluripotent stem cells (NIH Human Embryonic Stem Cell Registry line WA09 (H9) at passages [30] [31] [32] [33] [34] [35] according to a recently published protocol 17 and maintained in neural media composed of DMEM/F12 with sodium pyruvate and Glutamax, N2, B27, heparin and antibiotics. Media was either supplemented with growth factors (Epidermal Growth Factor (10 ng/ml) and Fibroblast Growth Factor (10 ng/ml)) or with Ciliary Neurotrophic Factor (10 ng/ml) during experiments. These cells show high levels of AXL expression (data not shown), in accordance with previously described transcriptional profiles of single fetal astrocytes 12 . hPSC-derived astrocytes were chosen due to their high fidelity to fetal astrocytes in vivo. All cell lines tested negative for mycoplasma using MycoAlert (Lonza).
Virus propagation and titering
ZIKV, strains SPH2015 (Brazil 2015, ZIKV-BR), PRVABC59 (Puerto Rico 2015, ZIKV-PR), and FSS13025 (Cambodia 2010, ZIKV-CAM), were propagated in vero cells infected at an MOI of 0.01.
Supernatants were collected at 72 and 96 hpi, clarified by centrifugation at 350 x g for 5 minutes, and filtered through a 0.45μm SFCA membrane. For mock infections supernatant was collected from uninfected vero cells and prepared by the same protocol used to make viral stocks. Virus was titered by plaque assay and focus assay. Briefly, plaque assays were performed using vero cells with a 0.7 % agarose overlay and processed five days post infection. Focus assays were performed on vero cells and processed 24 hpi with the anti-flavivirus group antibody (Millipore MAB10216, clone D1-4G2-4-15) at a dilution of 1:250. Titers determined by both methods were consistent. Each strain was sequence-verified using a previously published protocol 26 and all viral stocks tested negative for mycoplasma contamination by MycoAlert (Lonza). ZIKV-PR and ZIKV-CAM continued to test negative after prolonged incubation in culture (96 h). Contamination of ZIKV-BR with mycoplasma was detected at low levels after 72-96 h in culture. No other evidence of contamination was seen in cells infected with this viral strain.
Brain samples
De-identified primary tissue samples were collected with previous patient consent in strict observance of the legal and institutional ethical regulations. Protocols were approved by the Human Gamete, Embryo and Stem Cell Research Committee (institutional review board) at the University of California, San
Francisco.
Placenta samples
This study was approved by the UCSF Committee on Human Research. All donors provided written informed consent. The samples were processed immediately after they were acquired.
Chorionic villus explants and isolated cytotrophoblasts
Chorionic villous explants were prepared and CTBs were isolated by using previously described methods 27, 28 . Explants were cultured for 24 h prior to infection, which enabled attachment to a matrix substrate and extension of cell columns. Explants were incubated for 2 h with 5.6x10 5 pfu ZIKV-BR, 5.6x10 6 pfu ZIKV-CAM, or 1.1x10 6 pfu ZIKV-PR. Purified CTBs were infected at an MOI of 1 within 1 h of cell plating and incubated with virus for 2 h. Following incubation with virus, the media was replaced with fresh media prior to incubation for 24 or 48 h. As a negative control, conditioned medium from uninfected vero cells was processed according to the protocol that was used to make viral stocks (mock infection). The number of samples that were incubated with each strain of virus and the results (as determined by immunostaining for anti-flavivirus group antigen, see below) are summarized in Table 1 . Slices were cultured in a 37 °C incubator at 5% CO2, 8% O2 overnight. Slices were then incubated with 2.2x10 6 pfu ZIKV-BR, 1.1x10 7 pfu ZIKV-CAM, or 2.2x10 7 pfu ZIKV-PR for 4 h, before replacement with fresh media and culture for an additional 72 hpi. Tissue samples were fixed overnight in 4% paraformaldehyde.
Placental tissue immunohistochemistry
Placental tissue and explants were fixed, embedded and sectioned as described previously 29 . CTBs, attached to the tissue culture dish or transwell filters were fixed for 10 minutes in 3.7% paraformaldehyde and permeabilized with cold methanol. Double immunolocalization was performed as described previously 29 . Primary antibodies (mouse mAbs unless stated otherwise) were used at the following dilutions: rabbit mAb anti-AXL (10 ng/ml, Cell Signaling 8661), anti-CD68 (1:100, Dako, Clone KP1), anti-CK (1:200, 7D3 rat mAb, made in our laboratory 30 ), anti-flavivirus group antigen antibody (1:100, EMD Millipore MAB10216), or rabbit pAb anti-vWF (1:100, Novus Biologicals NB600-586). Binding of the primary antibodies was detected via FITC-conjugated secondary antibodies (anti-mouse or anti-rabbit) or rhodamine-conjugated anti-rat (Jackson ImmunoResearch) diluted 1:100. The samples were imaged by confocal microscopy (Leica SP5) or by using an epifluorescence microscope (Leica DM 5000B with a 350 FX camera).
Brain tissue immunohistochemistry
Heat-induced antigen retrieval was performed in 10 mM sodium citrate buffer, 
Immunoblotting
Preparation of lysates (from chorionic villi, purified CTBs or cultured astrocytes) and immunoblotting was done according to methods that we published previously 29 . The blots were probed with: rabbit mAb anti-AXL (Cell Signaling 8661), 10 ng/ml for placental lysates, 1:1000 for astrocyte lysates; rabbit mAb anti-LC3B (Cell Signaling 3868), 1:100 for placental lysates, 1:1000 for astrocyte lysates; rabbit pAb anti-p62
(Cell Signaling 5114), 1:100; anti-β-actin (SIGMA A441) for astrocyte lysates, 1:50,000, or anti-β-actin (C4, Santa Cruz Biotechnology SC47778) for placental lysates, 1:100. Binding of the primary antibodies was detected via peroxidase-conjugated antibodies (anti-mouse or anti-rabbit; Jackson ImmunoResearch) diluted 1:5,000 to 1:20,000. Quantitative measurements of the immunoblot signals were made by using scanning densitometry and ImageJ software.
Quantification of staining in human cortical sections
Images were quantified using Imaris v. 8 
AXL blocking
Cells were treated with AXL blocking antibody (R&D Systems AF154) or goat IgG control (R&D Systems AB108C) at 100 μg/mL for 1 h prior to infection with ZIKV, washed once and cultured for 48 h before immunostaining against envelope protein and DAPI. Percentage of infected cells was calculated as described for azithromycin dose-response experiments (below). 96% or 70% decrease for ZIKV-BR and ZIKV-PR respectively (n = 4 for each strain, p = 0.0003 or p = 0.0016 by 2-way ANOVA for ZIKV-BR and ZIKV-PR respectively). 
Cell viability assay
Evaluation of virus infectivity and infectious virus production
